Moj, D., Burhenne, J., Egerer, G., & Haefeli, W. E. (2017). A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer chemotherapy and pharmacology, 80(5), . https://doi.org/10.1007/s00280-017-3447-x
Chicago-Zitierstil (17. Ausg.)Moj, Daniel, Jürgen Burhenne, Gerlinde Egerer, und Walter E. Haefeli. "A Physiologically Based Pharmacokinetic and Pharmacodynamic (PBPK/PD) Model of the Histone Deacetylase (HDAC) Inhibitor Vorinostat for Pediatric and Adult Patients and Its Application for Dose Specification." Cancer Chemotherapy and Pharmacology 80, no. 5 (2017). https://doi.org/10.1007/s00280-017-3447-x.
MLA-Zitierstil (9. Ausg.)Moj, Daniel, et al. "A Physiologically Based Pharmacokinetic and Pharmacodynamic (PBPK/PD) Model of the Histone Deacetylase (HDAC) Inhibitor Vorinostat for Pediatric and Adult Patients and Its Application for Dose Specification." Cancer Chemotherapy and Pharmacology, vol. 80, no. 5, 2017, https://doi.org/10.1007/s00280-017-3447-x.